Altimmune, Inc. (NASDAQ:ALT) Short Interest Up 14.9% in April

Altimmune, Inc. (NASDAQ:ALT) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 20,370,000 shares, an increase of 14.9% from the March 31st total of 17,730,000 shares. Based on an average daily volume of 4,690,000 shares, the days-to-cover ratio is presently 4.3 days.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC lifted its stake in Altimmune by 62.0% in the third quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after buying an additional 69,014 shares during the period. Timelo Investment Management Inc. grew its position in shares of Altimmune by 2,597.0% during the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after buying an additional 779,095 shares during the period. GSA Capital Partners LLP increased its stake in shares of Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock valued at $1,159,000 after acquiring an additional 269,676 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Altimmune in the 4th quarter valued at approximately $534,000. Finally, Dark Forest Capital Management LP boosted its stake in Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock worth $599,000 after acquiring an additional 27,210 shares during the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Up 2.4 %

Shares of NASDAQ ALT opened at $6.55 on Wednesday. The firm’s 50-day moving average is $9.24 and its 200-day moving average is $7.61. Altimmune has a 1 year low of $2.09 and a 1 year high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. The firm had revenue of $0.04 million for the quarter. Altimmune had a negative net margin of 20,780.75% and a negative return on equity of 44.77%. As a group, analysts predict that Altimmune will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ALT. Guggenheim lowered shares of Altimmune from a “buy” rating to a “neutral” rating in a research report on Monday. The Goldman Sachs Group started coverage on Altimmune in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective on the stock. HC Wainwright cut their target price on Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, April 1st. Finally, B. Riley restated a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a research report on Thursday, March 28th.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.